https://www.gastroscan.ru/literature/pdf/acg02-gerd-treatment.pdf

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

Objective: T o de v elop a North American Society for Pediatric Ga str oen te rol og y , He pat olo gy , and Nut ri tio n (N ASP GH AN) and Eu rop ea n Soc ie ty fo r Pe di atr ic Gas tr oen te ro log y , Hep at ol og y , and Nut rit io n (ES PGH AN ) int er nat io nal con se ns us on th e di agn os is an d ma nag em ent of gas tr oes op hag eal refl ux and gas tr oes op hag eal re flu x di sea se in th e ped ia tr ic po pu la tio n. Methods: An international panel of 9 pediatric gastroenterologists and 2 epidemiologists were selected by both societies, which de v eloped these guidelines based on the Delphi principle. Statements were based on systematic literature searches using the best-av ailable e vidence from PubMed, Cumulati ve Index to Nursing and Allied Health Literature, and bibliographies. The committee con v ened in face-to-face meetings 3 times. Consensus was achie v ed for all recommendations through nominal group technique, a structured, quantitati v e method. Articles were e v aluated using the Oxford Centre for Evidence-based Medicine Le vels of Evidence. Using the Oxford Grades of Recommendation, the quality of e vidence of each of the recommendations made by the committee was determined and is summarized in appendices. Results: More than 600 articles were re vie wed for this work. The document provides e vidence-based guidelines for the diagnosis and management of gastroesophageal reflux and gastroesophageal reflux disease in the pediatric population. Conclusions: Th is do cum ent is int end ed to be us ed in dai ly pra cti ce fo r th e de v el op me nt of fut ure cli ni cal pra ct ic e gu ide lin es and as a bas is for cli ni cal tr ia ls . JP GN 49 :49 8 – 54 7, 20 09 . Ke y Wo rd s: Cli nic al pra ct ic e gu id el ine s — Di agn os tic te sts — Ga str oes op hag ea l refl ux (GE R) — Ga str oes op hag ea l refl ux di sea se (GE RD ) — The rap eut ic mod al iti es. # 20 09 by Eu rop ea n Soc ie ty fo r Pe di atr ic Gas tr oen te ro log y , Hep at ol og y , and Nut rit io n and No rt h Am er ica n So ci ety for Pe dia tri c Ga str oen te rol og y , Hep at ol og y , an d Nu tr iti on

/pdf/pediatric-gastroesophageal-reflux-clinical-practice-359og269ui.pdf

Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)

Clinical history, questionnaire data and response to antisecretory therapy are insufficient to make a conclusive diagnosis of GERD in isolation, but are of value in determining need for further investigation. Conclusive evidence for reflux on oesophageal testing include advanced grade erosive oesophagitis (LA grades C and D), long-segment Barrett’s mucosa or peptic strictures on endoscopy or distal oesophageal acid exposure time (AET) >6% on ambulatory pH or pH-impedance monitoring. A normal endoscopy does not exclude GERD, but provides supportive evidence refuting GERD in conjunction with distal AET

https://gut.bmj.com/content/gutjnl/67/7/1351.full.pdf

Modern diagnosis of GERD: the Lyon Consensus

To date, most concepts on the frequency of gastro-oesophageal reflux episodes and the efficiency of the antireflux barrier have been based on inferences derived from measurement of oesophageal pH. The development of intraluminal impedance monitoring has highlighted the fact that pH monitoring does not detect all gastro-oesophageal reflux events when little or no acid is present in the refluxate, even if special pH tracing analysis criteria are used. In November 2002, a workshop took place at which 11 specialists in the field of gastro-oesophageal reflux disease discussed and criticised all currently available techniques for measurement of reflux. Here, a summary of their conclusions and recommendations of how to achieve the best results from the various techniques now available for reflux measurement is presented.

https://gut.bmj.com/content/gutjnl/53/7/1024.full.pdf

Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux

https://gut.bmj.com/content/gutjnl/45/suppl_2/II31.full.pdf

Functional esophageal disorders.

https://www.gastrojournal.org/article/0016-5085(94)90123-6/pdf

Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus

https://www.gastrojournal.org/article/0016-5085(95)90156-6/pdf

Role of acid and duodenogastric reflux in esophageal mucosal injury: A review of animal and human studies

The symptom index is a quantitative measure developed for assessing the relationship between gastroesophageal reflux and symptoms. Controversy exists, however, over its accuracy and the appropriate threshold for defining acid-related symptoms of heartburn and chest pain. Therefore, a retrospective review was done of 153 consecutive patients referred to our esophageal laboratory. Three groups were identified: patients with normal 24-hr pH tests and no esophagitis, patients with abnormal 24-hr pH tests and no esophagitis, and patients with abnormal 24 hr pH values and endoscopic esophagitis. If symptoms occurred during the pH study, a symptom index (number of acid related symptoms/total number of symptoms x 100%) was calculated separately for heartburn and chest pain. Heartburn and chest pain episodes were similar among the three groups. However, the mean symptom index for heartburn was significantly (P<0.001) higher in the patient groups with abnormal pH values [abnormal pH/no esophagitis: 70±7.1% (±se); abnormal pH/esophagitis: 85±4.6%] as compared to those with normal studies, ie, functional heartburn (26±10.7%). The mean symptom index for chest pain was similar for all three groups. Using receiver operating characteristic curves, a heartburn symptom index≥50% had excellent sensitivity (93%) and good specificity (71%) for acid reflux disease, especially if patients complain of multiple episoldes of heartburn. In contrast, an optimal symptom index threshold for defining acid-related chest pain episodes could not be defined.

The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain.

The determinants of the oesophageal alkaline pH environment are poorly understood. Saliva (pH 6.4-7.8) may be a major contributor, although some argue the importance of refluxed alkaline duodenal contents. Acid and alkaline reflux parameters were studied over 2 days in 30 subjects (control, oesophagitis and Barrett's patients; 10 each) using glass pH electrodes. In phase 1, one pH electrode was placed 1 cm below the upper oesophageal sphincter to assess the influence of saliva and the other 5 cm above the lower oesophageal sphincter. Phase 2 was identical except that one pH probe was 5 cm below the lower oesophageal sphincter to record duodenogastric reflux. Patient groups spent, on average, 50 fold more time during the upright and supine periods at acidic pH than controls. Saliva was responsible for the percentage of time the pH > 7 and contributed significantly to the percentage of time the pH > 6 in both the proximal and distal oesophagus of control subjects, as shown by an absence of pH > 7 and a significant (p 6 during sleep. A similar pattern was seen in the proximal oesophagus of both reflux groups. The reflux and Barrett's patients, however did not show a significant decrease in the percentage of time the pH > 6 at night in the distal oesophagus suggesting a relative increase in 'alkaline' exposure from another source. This was not because of duodenogastric reflux as the corresponding pH rises in the fundus of the stomach were non-existent. Although this was not studied specifically, it is believed to be a protective meachanism, the result of alkaline secretion produced by submucosal oesophageal glands.

https://gut.bmj.com/content/gutjnl/34/3/309.full.pdf

Determinants of oesophageal 'alkaline' pH environment in controls and patients with gastro-oesophageal reflux disease.

Erythromycin, a possible motilin agonist, is a potent gastrokinetic agent that may increase the lower esophageal sphincter pressure. Therefore, we assessed the effects of erythromycin in two dosages (250 and 500 mgper os four times a day) on esophageal pH and pressure profiles in reflux patients using prolonged ambulatory monitoring systems. Studies were blinded, placebo-controlled with randomized crossover design. Patients took each drug for three days prior to studies, with erythromycin serum levels obtained the day of esophageal studies. Erythromycin 250 mg four times a day had no effect on esophageal contraction pressures or peristalsis during the day or meal periods. In the supine position, however, erythromycin significantly (P=0.012) decreased esophageal contraction velocity and showed a strong trend (P=0.059) towards increasing the percentage of peristaltic waves. Despite these potentially beneficial effects on esophageal clearance, no significant difference in acid exposure times during 24-hr pH studies were observed between placebo and low-dose erythromycin. High-dose erythromycin (500 mg four times a day) was associated with drug levels in the typical antibiotic efficacy range (normal 1–3 µg/ml; patients 1.7–7.0 µg/ml), but, here again, there was no significant difference in all acid reflux parameters between placebo and erythromycin phases. Therefore, “standard” doses of erythromycin have no important clinical effects on esophageal pressures or acid reflux parameters.

Swarnjit Singh

Papers

Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus

Role of acid and duodenogastric reflux in esophageal mucosal injury: A review of animal and human studies

The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain.

Determinants of oesophageal 'alkaline' pH environment in controls and patients with gastro-oesophageal reflux disease.

Effects of oral erythromycin on esophageal pH and pressure profiles in patients with gastroesophageal reflux disease.